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Abstract
Background: Routine administration of all age-appropriate doses of vaccines during the same 
visit is recommended for children by the National Vaccine Advisory Committee (NVAC) and the 
Advisory Committee on Immunization Practices (ACIP).
Methods: Evaluate the potentially achievable vaccination coverage for ≥4 doses of diphtheria 
and tetanus toxoids and acellular pertussis vaccine (4+DTaP), ≥4 doses of pneumococcal 
conjugate vaccine (4+PCV), and the full series of Haemophilus influenzae type b vaccine (Hib-
FS) with simultaneous administration of all recommended childhood vaccines. Compare the 
potentially achievable vaccination coverage to the reported vaccination coverage for calendar years 
2001 through 2013; by state in the United States and by selected socio-demographic factors in 
2013. The potentially achievable vaccination coverage was defined as the coverage possible for the 
recommended 4+DTaP, 4+PCV, and Hib-FS if missed opportunities for simultaneous 
administration of all age-appropriate doses of vaccines for children had been eliminated.
Results: Compared to the reported vaccination coverage, the potentially achievable vaccination 
coverage for 4+DTaP, 4+PCV, and Hib-FS could have increased significantly (P < 0.001), the 
vaccination coverage would have achieved the 90% target of Healthy People 2020 for the three 
vaccines beginning in 2005, 2008, and 2011 respectively. In 2013, the potentially achievable 
vaccination coverage increased significantly across all selected socio-demographic factors, 
potentially achievable vaccination coverage would have reached the 90% target for more than 51% 
of the states in the United States.
Conclusions: The findings in this study suggest that fully utilization of all opportunities for 
simultaneous administration of all age-eligible childhood doses of vaccines during the same 
vaccination visit is a critical strategy for achieving the vaccination coverage target of Healthy 
People 2020. Encouraging providers to deliver all recommended vaccines that are due at each visit 
by implementing client reminder and recall systems might decrease missed opportunities for 
simultaneous administration of childhood vaccines.
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1. Introduction
Routine administration of all age-appropriate doses of childhood vaccines during the same 
health care provider visit is the standard for childhood immunization practices and has been 
approved and recommended by the National Vaccine Advisory Committee (NVAC), the 
Advisory Committee on Immunization Practices (ACIP), the American Academy of 
Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) [1]. 
Simultaneous administration of childhood vaccines is defined as administering more than 
one recommended vaccine on the same visit day, at different anatomic sites, and not 
combined in the same syringe [2]. Simultaneous administration of all vaccines for which a 
child is eligible is an important strategy for ensuring that vaccinations are received on 
schedule, and for bringing children who have fallen behind on their vaccines up to date [3]. 
It is also an important standard crucial to increasing immunization rate, achieving and 
maintaining the national target of vaccination coverage level among children of 19–35 
months for all recommended vaccines [1–5]. Experimental evidence and extensive clinical 
experience show that giving all age-appropriate childhood vaccines simultaneously is a safe 
and efficacious practice [2,3,6]. Data from vaccination coverage surveys have indicated that 
failing to administer all vaccines for which a child is eligible is an important cause of low 
vaccination coverage [3]. Surveys of vaccination records from 21 selected cities and 
localities in the United States have shown that each child had many opportunities for the 
simultaneous administration of vaccines that, if used appropriately, could have potentially 
raised vaccination coverage levels by 12–22 percentage points with median of 17 percentage 
points [7]. A recent study from Nebraska has reported that 77% of children who were behind 
on their vaccinations at 24 months could have been up to date if appropriate vaccines had 
been given simultaneously [8]. A study from immunization record audits in the State of 
Georgia has demonstrated that vaccination coverage increased significantly when missed 
opportunities to administer vaccines simultaneously were reduced [9]. Missed opportunities 
for simultaneous vaccinations were recognized as one of the two main causes for children 
falling behind in their vaccination [10].
The studies cited above indicate that simultaneous administration of age-appropriate 
childhood vaccine could have increased children’s vaccination coverage rates significantly, 
but those results were limited to the selected states and local areas and did not evaluate the 
vaccination coverage that could be potentially achieved at the national level. Since 1995, the 
Centers for Disease Control and Prevention (CDC) has been estimating and reporting 
national, state, and selected local area vaccination coverage among children 19–35 months 
in the United States [11]. Those reports point out that vaccination coverage levels for most 
of the routine childhood vaccines have reached the Healthy People 2020 target of 90% [4]. 
However, vaccination coverage for ≥4 doses of diphtheria and tetanus toxoids and acellular 
pertussis vaccine (4+DTaP), ≥4 doses of pneumococcal conjugate vaccine (4+PCV), and the 
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full series of Haemophilus influenzae type b vaccine (Hib-FS) have not yet reached the 90% 
target. Therefore, in this current study, we applied the important immunization practice 
standard, i.e. simultaneous administration of childhood vaccines at the same visit, to the 
National Immunization Survey (NIS), the largest vaccination survey in the United States. We 
evaluated the potentially achievable vaccination coverage for 4+DTaP, 4+PCV, and Hib-FS 
for calendar years 2001 through 2013 in the United States; by 50 U.S. states and DC, and by 
selected socio-demographic factors in 2013. All potentially achievable vaccination coverage 
levels were compared to the corresponding reported vaccination coverage levels to assess the 
impact of simultaneous administration of childhood vaccines on vaccination coverage.
2. Methods
2.1. Data sources
National Immunization Survey (NIS) data collected from 2001 through 2013 were analyzed 
in this study. The NIS is conducted annually by the Centers for Disease Control and 
Prevention (CDC) to obtain national, state, and selected local area estimates of vaccination 
coverage for the U.S. non-institutionalized population of children 19–35 months [11]. The 
NIS is a random-digit-dialed telephone survey of households with age eligible children 
followed by a mail survey to children’s immunization providers to obtain provider-reported 
vaccination histories. Smith et al. [12] provide a detailed description of the complex survey 
design used by the NIS, which has been approved by CDC Institutional Review Board. 
Detailed descriptions of the 2001–2013 NIS and corresponding response rates have been 
published elsewhere [13–16].
2.2. Selected socio-demographic factors
The following socio-demographic factors available in the NIS related to the child, mother, 
family, and vaccination provider which have previously been found to be associated with 
childhood vaccination coverage in the United States were evaluated in this study, including 
child’s first born status (yes vs. no), number of children in the family (1 vs. ≥2), family 
poverty level (at/above vs. below poverty), family locality (urban, suburban, rural), mobility 
status since birth (not moved vs. moved), education level of mother (≤12 years vs. ≥13 
years), marital status of mother (married vs. not married), age group of mother (≤29 years 
vs. ≥30 years), and number (1 vs. ≥2) and type (public, other, private) of child’s vaccination 
providers. Children were defined as having health insurance if they were covered through 
the parents’ employer or union or by Medic-aid, S-CHIP, the Indian Health Service, Military 
Health Care, Tricare, Champus, Champ-VA, other health insurance, or another health care 
plan.
2.3. Outcome measures and definitions
Vaccines are recommended by ACIP for children during the first 2 years of life to protect 
them against 14 vaccine-preventable diseases and include: varicella, Haemophilus influenzae 
type b (Hib), measles, mumps, and rubella (MMR), rotavirus (RV), pneumococcal conjugate 
vaccine (PCV), diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated 
poliovirus (IPV), hepatitis A (HepA), hepatitis B (HepB), and influenza vaccines [4,17]. As 
reported by CDC, the vaccination coverage for 3+DTaP, 3+PCV, and the primary series of 
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Haemophilus influenzae type b (Hib-PS) have reached the 90% target for years, but for 
4+DTaP, 4+PCV, and the full series of Haemophilus influenzae type b (Hib-FS), the 
vaccination coverage have not achieved the 90% target yet [11]. Therefore we must focus on 
the last dose of vaccines in those 3 vaccination series. A missed opportunity was defined as 
the failure to administer the fourth dose of DTaP, the fourth dose of PCV, and the booster 
dose of Hib vaccine for the full series of Hib (Hib-FS), and during the same age eligible 
period, for the 3 vaccines just mentioned, when a child received one or more other needed 
and age appropriate vaccines [7]. Potentially achievable vaccination coverage was defined as 
the maximum coverage possible for the recommended 4+DTaP, 4+PCV, and Hib-FS if 
missed opportunities defined above had been eliminated [7].
The primary series of Haemophilus influenzae type b (Hib-PS) includes ≥2 or ≥3 doses of 
Hib vaccine depending on product type. The full series of Haemophilus influenzae type b 
(Hib-FS) includes ≥3 or ≥4 doses of Hib vaccine depending on product type received (i.e. 
includes the primary series plus the booster dose). In this current study, data analyses for Hib 
were limited to 2011–2013 because a shortage of Hib vaccine occurred in the United States 
during December 2007–September 2009 which resulted in an interim recommendation to 
defer the booster dose of Hib for Hib-FS; children included in the 2009 and 2010 NIS 
samples were affected by the temporary recommendation to suspend the booster dose of Hib 
for Hib-FS vaccine [13].
Because the pneumococcal conjugate vaccine shortages during 2001–2004 in the United 
States, the CDC recommended that all health care providers temporarily suspend routine 
administration of the fourth doses of PCV, thus children included in the 2001–2004 samples 
were affected by the deferring of the fourth dose of PCV [18]. Therefore the data from NIS 
2005 to 2013 were included and analyzed for the PCV vaccination study.
2.4. Statistical analyses
All of the analyses in this study were performed using SAS callable SUDAAN 11.0.0 [19], 
which properly accounts for the complex sampling survey design in the NIS. The potentially 
achievable and reported vaccination coverage, and the 95% confidence interval (CI) were 
estimated with weighted categorical data analyses procedures; t-tests were applied to 
compare the potentially achievable vaccination coverage with the reported vaccination 
coverage. The NIS methodology has been approved annually by the Ethics and Research 
Review Board of the National Center for Health Statistics since it was initiated in 1994.
3. Results
3.1. Potentially achievable vs. reported vaccination coverage for 4+DTaP, 4+PCV, and the 
full series of Hib (Hib-FS), 2001–2013
If the recommended standards of childhood immunization practices for simultaneous 
administration of the fourth dose of DTaP vaccine had been implemented fully according to 
the general ACIP recommended vaccination schedule, compared to the reported vaccination 
coverage for 4+DTaP, the potentially achievable vaccination coverage for 4+DTaP would 
have increased significantly each year from 2001 through 2013 (P < 0.001) (Fig. 1(A)). The 
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increases of vaccination coverage ranged from 3.9 percentage points to 7.2 percentage points 
with median of 6.7 percentage points. During 2001–2013, the potentially achievable 
vaccination coverage for 4+DTaP would have reached or been very close to the 90% target. 
Specifically beginning in 2005, the potentially achievable vaccination coverage for 4+DTaP 
would have reached or surpassed the 90% target specified by Healthy People 2020.
If missed opportunities for simultaneous administration of the fourth dose of PCV had been 
eliminated, the potentially achievable vaccination coverage for 4+PCV would be 
significantly higher than the reported vaccination coverage (P < 0.001) (Fig. 1(B)). 
Beginning in 2008, the potentially achievable vaccination coverage for 4+PCV would have 
reached and been significantly higher than the 90% target (P < 0.05). Simultaneous 
administration could have significantly increased the coverage for 4+PCV by 8.1 percentage 
points to 31.1 percentage points with median increase of 12.2 percentage points.
If all opportunities for simultaneous administration of the booster dose of Hib vaccine for 
Hib-FS had been taken, compared to the reported vaccination coverage for the full series of 
Hib, the potentially achievable vaccination coverage for the Hib-FS would have increased 
10.2 percentage points to 12.6 percentage points with median increase of 10.9 percentage 
points (Fig. 1(C)). The potentially achievable vaccination coverage for the full series of Hib 
would have been significantly higher than the reported vaccination coverage (P < 0.001). 
The potentially achievable vaccination coverage for the Hib-FS would have reached the 90% 
target beginning in 2011.
3.2. Potentially achievable vs. reported vaccination coverage by selected socio-
demographic factors in 2013
Potentially achievable vaccination coverage was compared to the reported vaccination 
coverage for 4+DTaP, 4+PCV, and the full series of Hib by selected socio-demographic 
factors (Table 1). If all opportunities for simultaneous administration of the fourth dose of 
DTaP, the fourth dose of PCV, and the booster dose of Hib vaccine for the full series of Hib 
(Hib-FS) had been used, compared to the reported vaccination coverage, the potentially 
achievable vaccination coverage would have increased significantly across each of the eleven 
selected socio-demographic factors for the three vaccine series at levels of P < 0.05, P < 
0.01, and P < 0.01 respectively. The potentially achievable vaccination coverage for 4+DTaP 
would have increased by 5.2 percentage points to 10.7 percentage points (median 7.1 
percentage points), for 4+PCV by 6.8 percentage points to 13.5 percentage points (median 
8.9 percentage points), for the full series of Hib by 7.4 percentage points to 14.8 percentage 
points (median 10.1 percentage points) across each of the eleven sociodemographic factors. 
The reported vaccination coverage for 4+DTaP was significantly lower than the Healthy 
People 2020 target of 90% at level of P < 0.01 over all selected socio-demographic factors 
except rural area, for which the difference was not significant at level of P < 0.05. The 
reported vaccination coverages for 4+PCV and the full series of Hib were significantly lower 
than the Healthy People 2020 target of 90% at level of P < 0.05 across all selected socio-
demographic factors. However, the potentially achievable vaccination coverage would have 
reached the 90% target for 14, 15, and 19 categories out of the total 24 categories from the 
11 factors by 4+DTaP, 4+PCV, and the full series of Hib respectively as presented in Table 1.
Zhao et al. Page 5
Vaccine. Author manuscript; available in PMC 2019 August 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3.3. Potentially achievable vs. reported vaccination coverage by state in the United States 
in 2013
If the fourth dose of DTaP had been administered simultaneously at all opportunities 
available, compared to the reported vaccination coverage, the potentially achievable 
vaccination coverage for 4+DTaP could have increased in 49 states and DC by 2.2 
percentage points to 12.7 percentage points (median 7.1 percentage points) (Fig. 2(A)). The 
only exception is Nevada for which an increase of 0.51% was observed. Moreover, for 19 
states and DC, the potentially achievable vaccination coverage would have increased 
significantly at level of P < 0.05. On the reported vaccination coverage for 4+DTaP, only five 
states reached the 90% vaccination coverage target; however, for the potentially achievable 
vaccination coverage, 27 states and DC would have reached 90% target in 2013.
If all opportunities for simultaneous administration of the fourth dose of PCV had been used 
appropriately, compared to the reported vaccination coverage, the potentially achievable 
vaccination coverage for 4+PCV would have increased across all 50 states and DC by 2.5 
percentage points to 17.8 percentage points (median 8.8 percentage points) (Fig. 2(B)). In 
addition, for 32 states and DC the potentially achievable vaccination coverage would have 
increased significantly at level of P < 0.05. On the reported vaccination coverage for 4+PCV, 
only six states achieved the 90% target; however, for the potentially achievable vaccination 
coverage, 35 states and DC would have reached the 90% target in 2013.
Had the recommendation for simultaneous administration of the booster dose of Hib for 
Hib-FS been in effect and adhered to, compared to the reported vaccination coverage, the 
potentially achievable vaccination coverage for the full series of Hib would have increased 
across all 50 states and DC (Fig. 2(C)) by 3.6 percentage points to 16.1 percentage points 
(median 9.4 percentage points). Also, for 42 states and DC the potentially achievable 
vaccination coverage would have increased significantly at level of P < 0.05. On the reported 
coverage for full series of Hib, only two states reached the 90% target; however, for the 
potentially achievable vaccination coverage, 39 states and DC would have reached the 90% 
target in 2013.
4. Discussion
Immunization recommendations in the United States currently target 14 vaccine-preventable 
diseases for children [4,17], it is very important to achieve the national immunization targets 
for children outlined in the Healthy People 2020, a nationwide health promotion and disease 
prevention agenda from the US Department of Health and Human Services. Achieving these 
objectives will improve the health and welfare of all children as well as the communities in 
which they live [4]. However, the regular calendar year estimates of vaccination coverage 
based on NIS indicate that the reported vaccination coverage for 4+DTaP, 4+PCV, and the 
full series of Hib for the U.S national and the majority of the states in the United States have 
been well below the 90% target level for years [11]. In order to increase vaccination 
coverage levels, one of the Immunization Strategies for Healthcare Practices and Providers is 
to reduce missed opportunities for simultaneous administration of childhood vaccines [5]. 
This current study applied that strategy to NIS data and demonstrated that if missed 
opportunities for simultaneous administration of childhood vaccines had been eliminated, 
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compared to the reported vaccination coverage, the potentially achievable vaccination 
coverage for 4+DTaP, 4+PCV, and the full series of Hib would have increased significantly, 
and could have achieved the 90% target in the United States. Rapid rise in reported 
vaccination coverage for 4+PCV between 2005 and 2008 likely reflects relative newness of 
PCV vaccine to the schedule (2000) and, in part, PCV shortages between 2001 and 2004.
An increasing proportion of children vaccination visits include simultaneous administration 
of childhood vaccines. Future introduction of new vaccines to protect against multiple 
diseases will further increase the number of injections at routine childhood vaccination 
visits. Parental and healthcare provider attitudes toward simultaneous administration of 
childhood vaccines may affect acceptance of recommended vaccines. An article [20] 
conducted a systematic review of the literature to examine factors underlying reported 
parental and healthcare provider concerns and practices related to simultaneous 
administration of childhood vaccines during the same vaccination visits. That study 
indicated that providers and parents report concerns about multiple vaccination, which tend 
to increase with increasing numbers of vaccination. Common parental and provider concerns 
included apprehension about the pain experienced by the child, worry about potential side 
effects, and uncertainty about vaccine effectiveness. That study pointed out that multiple 
studies reported that a positive provider recommendation to the parent and a high level of 
concern about the severity of the target disease were significantly associated with parental 
acceptance of simultaneous administration of childhood vaccines. Providers often 
significantly overestimated parental concerns about simultaneous vaccination, and their 
overestimation of parental concerns may lead them to postpone recommended vaccinations, 
which may result in extra visits and delayed vaccination. More research is needed on 
interventions to overcome provider and parental concern about simultaneous vaccination.
This study has some limitations that must be acknowledged. First, we assumed all visits for 
which we had data were eligible for vaccination. Because DTaP vaccination requires a 
minimum of 6 months interval between the third and fourth dose, we may have 
overestimated the frequency of missed opportunities for the fourth dose of DTaP and 
therefore overestimated the potentially achievable vaccination coverage for 4+DTaP. Second, 
we only evaluated healthcare visits when a vaccination was administered, however, there are 
other healthcare visits where missed opportunities may occur, such as acute care visits or 
follow-up visits. Therefore, in this current study, the assessment of the impact on vaccination 
coverage levels by eliminating missed opportunities for simultaneous administration of 
childhood vaccines is conservative [7]. Furthermore, if all of the other missed visit 
opportunities for childhood immunization could have been eliminated, then higher 
potentially achievable vaccination coverage levels might be attained. Finally, the annual 
surveys of the NIS from 2001 through 2010 used in this study collected data from 
households with a landline-phones, while the 2011 to 2013 surveys collected data from 
households with both landlines and cell-phones service. However, recent studies [21,22] 
indicated that the survey nonresponse and non-coverage bias in estimates of vaccination 
coverage might be quite small, the total survey error followed a normal distribution with 
mean of 1.72 percentage points (95% CI: 1.71–1.74 percentage points) and final adjusted 
survey weights corrected for this error. Although small, the largest contributor to the total 
survey error in terms of magnitude was nonresponse of immunization providers.
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Strategies designed to prevent missed opportunities have taken many different forms, used 
alone or in combination. Standing orders is the first. These are protocols whereby non-
physician immunization personnel may vaccinate clients without direct physician 
involvement at the time of the immunization. Standing orders are implemented in settings 
such as clinics, hospitals, and nursing homes. When used alone or in combination with other 
interventions, standing orders have had positive effects on immunization rates among 
children. Provider education is the second strategy. Anyone responsible for administering 
immunizations should be knowledgeable about principles of vaccination and vaccination 
scheduling, to the extent required for their position. Providers are largely responsible for 
educating their patients, so an investment in provider education will result in a higher level 
of understanding about immunizations among the public in general. Numerous educational 
materials, in a variety of formats, are available from CDC, the Immunization Action 
Coalition, and some state health departments, hospitals, or professional organizations. 
Incorporating some AFIX principles (i.e., assessment, feedback) into a provider education 
program might have a greater effect on provider behavior than an education effort aimed 
only at increasing knowledge. The last strategy is the Provider reminder and recall systems 
which use client reminder and recall interventions to remind parents that vaccinations are 
due (reminders) or late (recall), while effective in increasing immunization levels, can also 
help avoid missed opportunities if they are a component of other practices directed toward 
this goal. For example, if a reminder system is used consistently and staff members are 
knowledgeable about vaccination opportunities and valid contraindications, the system can 
be an additional aid in promoting appropriate immunization practices [5,23].
5. Conclusions
The findings in this study suggest that fully utilization of all opportunities for simultaneous 
administration of all age-eligible childhood doses of vaccines during the same vaccination 
visit is a critical strategy for achieving the vaccination coverage target of Healthy People 
2020. If simultaneous administration of all age-appropriate doses of vaccines had been fully 
carried out according to the general ACIP recommended vaccination schedule, potentially 
achievable vaccination coverage for 4+DTaP, 4+PCV, and Hib-FS could have reached the 
90% target of Healthy People 2020 at the levels of national, states, and socio-demographic 
factors in the United States. Encouraging providers to deliver all recommended vaccines that 
are due at each visit by implementing client reminder and recall systems might decrease 
missed opportunities for simultaneous administration of childhood vaccines.
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Fig. 1. 
Potentially achievable vs. reported vaccination coverage and 95% confidence interval for 
4+DTaP*, 4+HPV†, Hib-FS§, National Immunization Survey, United States, 2001–2013. 
*≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 
doses of pneumococcal conjugate vaccine (PCV). § Full series Haemophilus influenzae type 
b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine 
depending on product type received (includes primary series plus the booster dose). Footnote 
for (B): Because of the pneumococcal conjugate vaccine shortages during 2001–2004 in the 
United States, children included in the 2001–2004 samples were affected by the deferring of 
the fourth dose of PCV, therefore the data from NIS 2005–2013 were included for the PCV 
vaccination study. Footnote for (C): Hib data were limited to 2011–2013 because a shortage 
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of Hib vaccine occurred in the United States during December 2007 to September 2009, 
children were affected by the temporary recommendation to suspend the booster dose of Hib 
for Hib-FS vaccine.
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Fig. 2. 
Potentially achievable vs. reported vaccination coverage and 95% confidence interval for the 
4+DTaP*, 4+PCV†, Hib-FS§, by State in the United States, National Immunization Survey, 
2013. * ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † 
≥4 doses of pneumococcal conjugate vaccine (PCV). § Full series Haemophilus influenzae 
type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus influenzae type b (Hib-FS) vaccine 
depending on product type received (includes primary series plus the booster dose).
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